title: [Relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice].
abstract: OBJECTIVE
  To investigate the relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice.
  
  
  METHODS
  Different gene type mice (TNFR1(+/+), TNFR1(+/-) and TNFR1(-/-)) with the same genetic background of C57BL/6 were used in this experiment. Murine lymphoma EL4 cells were inoculated subcutaneously into the different gene type mice simultaneously. Twelve days later, 7.5 mg/kg melphalan was used intraperitoneally to treat the tumor-bearing mice with TNFR1(+/+), TNFR1(+/-) and TNFR1(-/-). The tumors in the different gene type mice were observed and recorded every one to three day.
  
  
  RESULTS
  After the treatment of 7.5 mg/kg melphalan during the first week, the tumors in the different gene type mice shrank at a similar rate. In the following 2 months, the tumors in the TNFR1(+/+) and TNFR1(+/-) C57BL/6 mice gradually shrank and were cured but most tumors in the TNFR1(-/-) C57BL/6 mice relapsed after melphalan treatment.
  
  
  CONCLUSIONS
  TNFalpha plays an important role in melphalan-induced tumor rejection. The anti-tumor effect of melphalan has no relationship with the expression of tumor necrosis factor 1 in tumor-bearing mice. TNFR1 is required to prevent or avoid the relapse of tumors in mice instead of tumor cells.
authors.affiliation: Department of Pathophysiology, Dalian Medical University, Dalian 116027, China.
authors.forename: Mo-Lin
authors.initials: ML
authors.lastname: Li
authors.forename: Chuan-Gang
authors.initials: CG
authors.lastname: Li
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Shu
authors.forename: Miao-Na
authors.initials: MN
authors.lastname: Jiang
authors.forename: Yu-Jie
authors.initials: YJ
authors.lastname: Jia
authors.forename: Zhi-Hai
authors.initials: ZH
authors.lastname: Qin
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005838:Genotype; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D047888:Receptors, Tumor Necrosis Factor, Type I; C506236:Tnfrsf1a protein, mouse; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan